Partner Headlines - ALKS

  1. Last London Letter

    TalkMarkets
  2. Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech? ...

    TalkMarkets
  3. Trump Triumphs

    TalkMarkets
  4. Biotech Bear Market Looking For Relief From Q3 Large Cap Growth

    TalkMarkets
  5. Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex ...

    TalkMarkets
  6. Alkermes bounces back after disappointments as depression drug ...

    TalkMarkets
  7. Jefferies Sees 'Attractive Buying Opportunities' In Biotech

    TalkMarkets
  8. Has Gold Lost Its Glimmer?

    TalkMarkets
  9. Alkermes down after drug fails

    IBD
  10. Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes ...

    Benzinga
  11. Alkermes Hits Two-Year Low On Depression Drug Failure

    IBD
  12. Mid-Day Market Update: US Stocks Turn Higher; Plexus Shares Gain ...

    Benzinga
  13. Mid-Morning Market Update: Markets Drop; Verizon Profit Tops ...

    Benzinga
  14. 10 Stocks Moving In Thursday's Pre-Market Session

    Benzinga
  15. AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week ...

    GuruFocus
  16. Alkermes Reports Achievement of Milestones for CNS Medicines ...

    Benzinga
  17. U.S.-Traded Eurozone Stocks React Mildly To ECB Vote

    IBD
  18. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  19. Non-Opioid Therapeutics And Significant Pain Treatments Make ...

    Benzinga
  20. Benzinga's Volume Movers

    Benzinga
  21. Morning Market Gainers

    Benzinga
  22. Underappreciated Leader Skips Over Equal-Weight In Double Upgrade

    Benzinga
  23. Benzinga's Top #PreMarket Gainers

    Benzinga
  24. Benzinga's M&A Chatter for Tuesday June 16, 2015

    Benzinga
  25. US Stock Futures Decline Ahead Of Housing Starts Report

    Benzinga
  26. Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming ...

    Benzinga
  27. Alkermes Reports Phase 3 Study Results for Aripiprazole Lauroxil ...

    Benzinga
  28. US Stock Futures Edge Lower; GDP Report In Focus

    Benzinga
  29. Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting ...

    Benzinga
  30. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  31. Benzinga's Top Initiations

    Benzinga
  32. Barclays Initiates Alkermes With Overweight

    Benzinga
  33. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  34. Stocks Mostly Higher: Time Warner Clears Buy Point

    IBD
  35. Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

    Benzinga
  36. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  37. Alkermes pops to 15-year high

    IBD
  38. Alkermes Hits High On Schizophrenia Drug Results

    IBD
  39. Morning Market Gainers

    Benzinga
  40. Benzinga's Top #PreMarket Gainers

    Benzinga
  41. Benzinga's Volume Movers

    Benzinga
  42. 3 Biotech ETFs Rally On Merger News

    Benzinga
  43. Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga
  44. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  45. Alkermes Announces Completion Of Patient Enrollment In Phase ...

    Benzinga
  46. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  47. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  48. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  49. Alkermes' drug passes trial

    IBD
  50. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  51. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  52. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  53. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  54. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  55. Benzinga's Volume Movers

    Benzinga
  56. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  57. Morning Market Movers

    Benzinga
  58. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  59. Benzinga's Top Initiations

    Benzinga
  60. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  61. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  62. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  63. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  64. Stocks End Short Week With Big Losses

    IBD
  65. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  66. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  67. Ireland Home To Several Fast Growing Health Care Names

    IBD
  68. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  69. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  70. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  71. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  72. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  73. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  74. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  75. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  76. Alkermes

    IBD
  77. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  78. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  79. Alkermes

    IBD
  80. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  81. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  82. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  83. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  84. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  85. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  86. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  87. Stocks Pare Early Losses, End With Modest Declines

    IBD
  88. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  89. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  90. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  91. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  92. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  93. Dow Leads Market Higher As Volume Swells

    IBD
  94. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  95. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  96. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  97. Stocks Tumble On Disappointing Earnings Reports

    IBD
  98. Why Cisco, Google And Apple All Became Big Winners

    IBD
  99. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  100. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
Trading Center